Highmark Commercial Medical Policy - Pennsylvania |
Medical Policy: | I-145-004 |
Topic: | Testosterone Androgens |
Section: | Injections |
Effective Date: | October 1, 2017 |
Issue Date: | October 2, 2017 |
Last Reviewed: | July 2017 |
Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. |
This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.
Policy Position Coverage is subject to the specific terms of the member’s benefit plan. |
Drugs addressed in this policy include injectable testosterone products categorized as androgens, which include:
Testosterone injections may be considered medically necessary in males when the following criteria are met:
Testosterone injections may be considered medically necessary for palliative treatment in females with metastatic breast cancer (testosterone enanthate or testosterone cypionate).
Testosterone injections may be considered medically necessary for transgender individuals who meet ALL the following:
Testosterone injections not meeting the above criteria, or for any other indications are considered not medically necessary.
NOTE: Dosage recommendations per the FDA label. Refer to pharmacy policy J-197, Testosterone Androgens, for additional information |
Place of Service: Inpatient/Outpatient |
The administration of testosterone androgens is typically an outpatient procedure which is only eligible for coverage as an inpatient procedure in special circumstances, including, but not limited to, the presence of a co-morbid condition that would require monitoring in a more controlled environment such as the inpatient setting.
The policy position applies to all commercial lines of business |
Denial Statements |
Services that do not meet the criteria of this policy will not be considered medically necessary. A network provider cannot bill the member for the denied service unless: (a) the provider has given advance written notice, informing the member that the service may be deemed not medically necessary; (b) the member is provided with an estimate of the cost; and (c) the member agrees in writing to assume financial responsibility in advance of receiving the service. The signed agreement must be maintained in the provider’s records.
Links |
11/2015, Clinical Criteria Established for Testosterone Androgens Facility application Added.